Your AI-Trained Oncology Knowledge Connection!
Howard L. “Jack” West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent <em>EGFR</em>-mutant non-small cell lung cancer (NSCLC).
Catherine Shu, MD, medical oncologist, Division of Hematology/Oncology, Columbia University Medical Center, discusses two clinical trials exploring the use of bevacizumab (Avastin) in patients with non-small cell lung cancer.
The majority of patients with non–small cell lung cancer do not harbor an actionable marker, calling for future research into optimal therapies and combinations for patients with non-driver adenocarcinoma.
The promising clinical efficacy seen with the combination of erlotinib and bevacizumab as a treatment for patients with <em>EGFR</em>-mutant non–small cell lung cancer warrants widespread consideration.
Raymond Osarogiagbon, MD, medical oncologist, Baptist Memorial Medical Group, discusses the significance of surgery quality in non-small cell lung cancer (NSCLC).
Several practice-changing developments are on the horizon in subsets of non–small cell lung cancer.
Targeted therapies have revolutionized the treatment of patients with non–small cell lung cancer; however, not all patients harbor identifiable driver mutations. Standard treatment options among patients lacking molecular targets include chemotherapy and antiangiogenesis agents.
The pathological response following pre-operative cisplatin, pemetrexed, and bevacizumab treatment may serve as a surrogate marker for post-surgical recurrence-free survival in patients with non-squamous non–small cell lung cancer.
